A novel pill that blocks the hormone aldosterone shows promise for lowering blood pressure and potentially delaying the progression of kidney disease in people with both conditions. The preliminary findings were presented Saturday at an American Heart Association meeting in Baltimore and simultaneously published in the Journal of the American Society of Nephrology. The Phase 2 clinical trial, known as FigHTN, found that the new medication, baxdrostat, yielded a roughly 5% reduction in systolic